US FDA best practices for initiating early feasibility studies for neurological devices in the United States.
PMID: 34087794 ·
R, o, b, e, r, t, , H, e, r, r, m, a, n, n, ;, , M, a, u, r, e, e, n, , D, r, e, h, e, r, ;, , A, n, d, r, e, w, , F, a, r, b, ;, , M, i, c, h, a, e, l, , H, o, f, f, m, a, n, n, ;, , C, h, r, i, s, t, o, p, h, e, r, , M, , L, o, f, t, u, s, ;, , N, i, n, a, , M, e, z, u, -, N, w, a, b, a, ;, , V, i, v, e, k, , P, i, n, t, o, ;, , X, i, a, o, l, i, n, , Z, h, e, n, g, ;, , C, a, r, l, o, s, , P, e, ñ, a
Publicidade
Resumo
This article describes the efforts of the US Food and Drug Administration (FDA) Office of Neurological and Physical Medicine Devices to facilitate early clinical testing of potentially beneficial neurological devices in the US. Over the past 5 years, the FDA has made significant advances to this aim by developing early feasibility study best practices and encouraging developers and innovators to initiate their clinical studies in the US. The FDA uses several regulatory approaches to help start n
Publicidade
Fonte oficial
Ver no PubMed →Dados provenientes do PubMed / NCBI. Para consultar o texto integral e as informações mais recentes, recorra sempre ao registo oficial.